



DEFINITIVE



Who we are

DEFINITIVE is a multidisciplinary European consortium bringing together key stakeholders and 41 clinical centres to improve the quality of life of HER2-positive breast cancer patients.

What we are working on

DEFINITIVE evaluates whether the HER2DX genomic test can personalise treatment, maintain effectiveness, improve quality of life and optimise healthcare resources. The test developed by Reveal Genomics, analyses tumour biology to predict prognosis and treatment response.

What's the one thing we need next

With 304 patients included in the trial, we need to complete the data collection, analyse the robust evidence, and support the integration of HER2DX into routine care across Europe.

**5 years Mission Cancer:
Stronger Through Connection**

BRUSSELS

29 SEPTEMBER – 01 OCTOBER



For more info visit:
www.thedefinitivetrial.eu





EUROPEAN UNION

DEFINITIVE

Diagnostic HER2DX-guided treatment for patients
with early-stage HER2 positive breast cancer.

